Sodium- and chloride-dependent creatine transporter 1 (CT1 (also SLC6A8))

Sodium– and chloride-dependent creatine transporter 1 is a plasma membrane protein encoded by the SLC6A8 gene. It mediates active transport of creatine into cells using sodium and chloride gradients. This process is essential for maintaining cellular energy homeostasis—especially critical in tissues with high energy demands such as skeletal muscle and brain. Defects or loss-of-function mutations lead to X-linked cerebral creatine deficiency syndrome characterized by intellectual disability, developmental delay, seizures, behavioral disturbances, and muscle weakness due to insufficient intracellular stores of phosphocreatine. The primary clinical intervention involves dietary supplementation with oral creatine; however efficacy depends on residual activity/functionality of this specific transporter protein within affected individuals[2][3][5].

Other names

Creatine transporter 1CT1SLC6A8CRTCRTRSC6A8_HUMANSolute carrier family 6 member 8

Drugs or supplements targeting this molecule typically: Increase intracellular creatine by facilitating its transport into cells via CT1/SLC6A8. Address deficiencies caused by mutations that impair normal function of the transporter.